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Summary Respiratory failure is an important terminal event in muscular
dystrophy, but increasingly is effectively treated by non-invasive ventilation. This
study was designed to assess mortality statistics in this patient group in order to get
an indication of future demand.
Mortality data for all deaths from muscular dystrophy registered by death
certification in England and Wales between 1993 and 1999 were analysed.
In total, 817 deaths from muscular dystrophy were registered between 1993 and
1999. Annual number of deaths was unchanged over this period. Median age at death
(interquartile range) for all cause muscular dystrophy increased from 20 (17–42.5)ee front matter & 2005
med.2005.09.030
ing author at: Departme
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ess: lori.calvert@uhl-tr.years in 1993, to 26 (17.5–63) years in 1999. Respiratory failure was the primary or
contributory cause of death in 82% of cases. Two thirds of these deaths were during
acute infection.
We can expect 100 patients with muscular dystrophy to develop respiratory
failure in England and Wales each year, so non-invasive ventilation services probably
need to be able to provide for 0.2 new patients per 100,000 population annually.
Respiratory services also need to provide adequate monitoring and early treatment
of infection in these patients.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Respiratory failure, often exacerbated by respira-
tory infection, is an important cause of death in
patients with muscular dystrophy. Since the early
1990s there has been a significant rise in the use of
non-invasive ventilation (NIV) in this population, as
it has become widely accepted as an effective
means of managing respiratory failure. NIV has
subsequently resulted in substantial improvements
in survival in patients with slowly progressive
muscular dystrophy.1–3 Even in more rapidly pro-
gressive conditions such as Duchenne muscular
dystrophy (DMD), NIV has been shown to prolong
life by several years.4 As a consequence, the
number of patients with muscular dystrophy using
NIV at home is steadily increasing.5,6 Since respira-
tory decompensation often occurs at the crucial
time when patients are in the process of moving
from paediatric to adult services, patients with
muscular dystrophy are increasingly being referred
to adult respiratory services for respiratory support
and consideration of NIV.
In order to provide an adequate service for
patients with muscular dystrophy, we need some
indication of their future needs and the likely
impact on respiratory services, and in particular
NIV services, by this population. However, there is
very little epidemiological data in the current
literature on which to base any assessment of
service requirements. The aim of this study is to
collect detailed information on the pattern of
number of deaths and age at death over time and
on cause of death. We have therefore examined
mortality statistics for all causes of muscular
dystrophy in England and Wales over a 7-year period.
This information can then be used to estimate future
demand for respiratory services in this population.Methods
The time trend in age at death and the effects of
diagnostic category of muscular dystrophy and
gender have been examined. We have also looked
for any geographical variation in age at death that
might reflect the presence of specialist clinics for
the provision of NIV, and have examined the effects
of social class as a possible marker of access to and
uptake of NIV services.
Data collection
Mortality data for all deaths with muscular dystro-
phy mentioned on the death certificate wereobtained from the National Statistics Office for
the period 1993–1999. The data included the
underlying cause of death, age at death, place of
death, gender, regional health authority of usual
residence, and occupational social class.
Underlying cause of death has been documented
as text as supplied on the death certificate
under Sections 1a, 1b, and 1c and classified as
respiratory, cardiac, cardio-respiratory, muscular
dystrophy or other. Age at death was recorded as
age in years at the last birthday. Five diagnostic
categories of muscular dystrophy were identified
for the purpose of analysis—DMD, muscular
dystrophy (unspecified), Beckers muscular dystro-
phy (BMD), limb girdle or facioscapulohumoral
muscular dystrophy (LG/FSH), congenital muscular
dystrophy and other muscular dystrophy (orophar-
yngeal, neuroaxonal, pseudohypertrophic, Emery
Dreifess, Barths type, myotonic, scapuloperoneal,
familial, merosine positive, spinal, ischemic, auto-
somal recessive).
Coding for regional health authorities corre-
sponds to their reorganisation in 1996. Social class
included an occupational code for the deceased if
aged over 16 or the mother’s occupation if under
16, and, respectively, for the spouse or father.
Categories are professional and intermediate,
skilled non-manual, skilled manual, semi-skilled,
unskilled, and other/unknown. For the purpose of
analysis the higher occupational social class was
used.
Statistical analysis
The data was analysed in terms of median age at
death by calendar year in relation to diagnostic
category of muscular dystrophy and gender. De-
scriptive analyses were carried out using Microsoft
Excel.
The independent effects of gender, diagnosis,
social class, and health authority region of usual
residence on the odds of death above the median
age for the year of death were estimated by
multiple logistic regression (effects were examined
in the three most common diagnostic categories)
[SPSS version 10].Results
A total of 817 people (677 males) were registered
as having died from muscular dystrophy in England
and Wales between 1993 and 1999. Table 1 shows
number of deaths each year by diagnostic category
and gender.
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Figure 1 Annual median age (interquartile range) at
death from all cause muscular dystrophy in England and
Wales 1993–1999.
L.D. Calvert et al.1060Median age (interquartile range) at death for all
cause muscular dystrophy increased significantly
from 20 (17–42.5) years in 1993 to 26 (17.5–63)
years in 1999 (P ¼ 0:042) (Fig. 1). The trend for
median age at death over time for the three main
diagnostic categories, DMD, muscular dystrophy
(unspecified) and BMD, is shown in Fig. 2. Median
age at death for DMD did not change over the 7-
year period (18 years in 1993 and 18.5 years in
1999), but the interquartile range widened (16–20
years in 1993 and 16–22.25 years in 1999).
Odds of death above median age were signifi-
cantly higher in women than in men and this trend
persisted when X-linked causes for muscular dys-
trophy were excluded from the analysis OR 6.6 (95%
CI 2.8–15.2). The mutually adjusted odds ratios for
these effects, after excluding X-linked causes, are
shown in Table 2.
There was no significant regional variation in
odds of death above median age for all cause
muscular dystrophy or on subgroup analysis. TheTable 1 Number of deaths from muscular dystrophy eac
category of muscular dystrophy and by gender.
Diagnostic category Year
1993 1994 1995
DMD
Male 75 37 41
Female 0 2 0
MD
Male 46 44 32
Female 14 11 13
BMD
Male 4 5 6
Female 0 0 0
FSH
Male 1 1 1
Female 1 1 0
Limb girdle
Male 1 1 1
Female 3 1 0
Cong
Male 2 1 2
Female 0 1 1
Other
Male 3 1 5
Female 0 1 3
Total 150 107 105
Abbreviations: DMD ¼ Duchenne muscular dystrophy; MD ¼ m
dystrophy; FSH ¼ facioscapulohumoral muscular dystrophy; Limb
muscular dystrophy; 0ther ¼ other causes of muscular dystrophy.odds of death above median age were unrelated to
occupational social class.
Analysis of cause of death (Fig. 3) confirms that
the majority were due to respiratory failure (59%),h year in England and Wales 1993–1999 by diagnostic
Total
1996 1997 1998 1999
53 43 51 51 351
0 1 0 1 4
31 31 27 28 239
13 21 9 16 97
2 5 5 7 34
0 0 0 0 0
2 2 4 3 14
3 2 1 2 10
2 0 0 2 7
1 1 2 3 11
1 3 3 1 13
1 2 0 0 5
3 0 1 6 19
4 1 1 3 13
116 112 104 123 817
uscular dystrophy (unspecified); BMD ¼ Beckers muscular
girdle ¼ limb girdle muscular dystrophy; Cong ¼ congenital
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failure. Deaths documented as ‘muscular dystro-
phy’ are most likely to be respiratory or cardio-
respiratory. Therefore respiratory failure may con-
tribute up to a total of 82% of deaths.
Of the respiratory deaths, 327 (68%) were due to
pneumonia/acute infection and 150 (31%) due to
chronic respiratory failure. Other causes were
documented as respiratory arrest (4) and pulmon-
ary hypertension (1).
Analysis by diagnostic category shows confirmed
respiratory deaths account for 56% of deaths in
DMD, 65% in muscular dystrophy (unspecified), 35%
in BMD, 56% in limb girdle muscular dystrophy, 67%
in facioscapulohumoral muscular dystrophy, 67% in
congenital muscular dystrophy and 53% in other
muscular dystrophy.Table 2 Odds of death from muscular dystrophy at a
diagnosis and occupational social class.
Category % Above median
Gender
Men 39.7
Women 90.7
Diagnosis
DMD 13.8
MD 73.2
BMD 91.2
Social class
Professional and intermediate 57.7
Skilled non-manual 74.2
Skilled manual 60.3
Semi skilled 64.4
Unskilled 76.5
Other/unknown 39.1
Abbreviations: DMD ¼ Duchenne muscular dystrophy; MD ¼ m
dystrophy.
Three largest diagnostic categories: DMD, MD and BMD.
yAdjusted for other variables in the table.
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Figure 2 Annual median age (interquartile range) at
death in muscular dystrophy by diagnostic category
(Three largest diagnostic categories: DMD, MD and BMD)
in England and Wales 1993–1999.Most deaths (59%) occurred in hospital and only
27% of deaths occurred at home.Discussion
This study has found that the number of deaths
each year from all causes of muscular dystrophy in
England and Wales is unchanged between 1993 and
1999, but that median survival had increased to 26
years by 1999. The majority of deaths can be
attributed to respiratory causes (82%), and 68%
occur during acute infection. A high proportion of
patients die in hospital.
Although our data may not comprise a complete
record of all patients dying with muscular dystro-
phy due to misclassification or under-reporting on
the death certificate, most patients with significant
disease are likely to be included. Death certificatebove median age in any year according to gender,
Adjusted odds ratioy 95%confidence interval
1.0
9.5 4.1–22.1
1.0
11.1 7.3–16.6
57.1 16.6–196.5
1.0
2.1 0.8–5.6
0.8 0.3–2.1
1.3 0.5–3.8
2.0 0.6–6.7
0.5 0.3–1.1
uscular dystrophy (unspecified); BMD ¼ Beckers muscular
Other
  3%Cardiac
  15%
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           19%
Cardio-respiratory
          4%
Respiratory
      59%
Figure 3 Cause of death in muscular dystrophy in
England and Wales 1993–1999.
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L.D. Calvert et al.1062accuracy is high for rare fatal diseases such as
muscular dystrophy, which are chronic and have
high diagnostic accuracy. Furthermore, annual
numbers of death recorded here are comparable
to estimated rates based on expected incidence of
muscular dystrophy in the UK. It is possible that X-
linked muscular dystrophy has been miscoded
under muscular dystrophy (unspecified), but this
does not appear to have had a significant influence
on our results, since our analyses were similar when
X-linked muscular dystrophy was excluded. We
have no data on current survivors but it seems
reasonable to assume that the affects of health
authority region and social class are similar
amongst survivors and those who have died. Women
with muscular dystrophy live longer than men, even
when X-linked muscular dystrophy is excluded from
analysis. This was unexpected and a possible
explanation for this is miscoding of X-linked
muscular dystrophy under the more general mus-
cular dystrophy codes. However, a true survival
benefit for the female gender remains.
There is now good evidence for the role of long-
term NIV in the treatment of respiratory complica-
tions of muscular dystrophy,3 and its use in this
population has rapidly expanded over the past 15
years. Improvements in survival from DMD have
been demonstrated at 2 years7 and 5 years.4
Rideau8 has shown that without ventilatory support
mean age of death in DMD was 19 years with 73%
occurring as a consequence of respiratory failure.
In UK specialist centres, NIV had improved mean
survival to 25.3 years by the end of the 1990s.9
Therefore the median age at death from DMD in this
survey is lower than expected and did not increase
over time. This suggests that the use of NIV in this
population over the period examined may have
been low compared with its use across Europe. The
years examined in this study correspond to a time
of growing acceptance for a role of NIV in muscular
dystrophy in the UK,10 and it is possible that after
1999 there have been improvements in age at
death due to the use of NIV. It is now recommended
that NIV should be considered in all patients with
muscular dystrophy developing symptomatic hyper-
capnic respiratory failure. Although not all patients
with muscular dystrophy will be suitable for NIV, an
increasing proportion of them are being referred to
respiratory services for assessment for this form of
treatment as awareness of the benefits become
more widely appreciated.11 This may be reflected
in our data by the widening of the interquartile
range due to an increase in the upper quartile,
indicating that a cohort of patients are living
longer. This is likely to be due to the introduction
of NIV.From our data, we would expect up to 100
patients with muscular dystrophy to die from
respiratory failure each year in the UK (population
60 million). This can be used as a guide to the likely
demand on respiratory services from this popula-
tion group. A recent European study estimates the
prevalence of home mechanical ventilation users as
4.1 per 100,000 population in the UK12 and 40%
have neuromuscular disease, which includes mus-
cular dystrophy as its largest group. A further 35%
have thoracic cage abnormalities and 25% have lung
and airways diseases. Although it is difficult to
predict the proportion of patients for whom NIV
would be suitable and indicated, our data suggests
that NIV services in England and Wales probably
need to be able to provide for a further 0.2 new
patients with muscular dystrophy and respiratory
failure per 100,000 population each year. Patients
with muscular dystrophy often remain on NIV for
longer than other patient groups13 and this should
be taken into account when planning service
requirements. Currently, in the UK only a small
percentage of patients with muscular dystrophy use
NIV via a tracheostomy.13
Regular monitoring of pulmonary function at
home has been advocated for this group of
patients, in order to identify early the need for
cough assist and NIV. When patients are admitted,
it is important that they are seen at a centre that
can provide these facilities. However, previous
surveys have suggested that 55% of home mechan-
ical ventilation in neuromuscular disease is started
non-electively during acute infections14 and we
found that two thirds of patients with muscular
dystrophy die during acute respiratory infection.
Firstly, this may represent a cohort of patients
where NIV needs to be considered at an earlier
stage. Secondly, the high proportion of patients
developing infective respiratory complications as a
terminal event must to taken into account when
developing respiratory service provision for this
population. The high proportion of deaths in
hospital also raises the question of whether
advance directives and palliative care facilities
are being used optimally for these patients.
We were unable to demonstrate any effect of
region of residence on age of death, which
argues against any major inequity in provision or
access to healthcare for muscular dystrophy pa-
tients within England and Wales. Similarly, there
was no effect of occupational social class, suggest-
ing that access to healthcare is not an important
factor in survival. However, our database may be
too small to detect such effects and it would be
useful to reanalyse this once a larger database has
been built up.
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Survival from muscular dystrophy and impact on services 1063In conclusion, we have found that respiratory
failure, often associated with acute respiratory
infection, accounts for a significant number of
deaths in patients with muscular dystrophy. Based
on current mortality statistics, we suggest that the
number of new patients with muscular dystrophy
and respiratory failure that NIV services in England
and Wales need to provide for each year is 0.2 per
100,000 population. In addition, respiratory ser-
vices should have the resources for adequate
monitoring and early treatment of infective ex-
acerbations in this patient group.Acknowledgement
We thank Glenn Meredith from the Office for
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